China’s Mindrank raised $52 million in a Series B to advance MDR-001, its AI-discovered oral GLP-1 receptor agonist, which is in Phase III development for obesity in China. The company tied the funding to scaling its Molecule Arts Platform and supporting ongoing late-stage execution. The financing underscores a competitive push toward oral GLP-1 formulations as regulators and payers weigh routes of administration, and as incumbents seek broader label coverage beyond injections. With MDR-001 already in Phase III, Mindrank’s fundraising reflects an emphasis on clinical delivery rather than early discovery only. For investors and pharma partners, the round also signals that AI-native discovery companies are reaching capital-efficient stages when they can demonstrate that candidates can clear major preclinical and clinical hurdles.